Patents by Inventor Zofia J. Chrzan

Zofia J. Chrzan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE NON-HYGROSCOPIC CRYSTALLINE FORM OF N-[N-[N-(4-(PIPERIDIN-4-YL)BUTANOYL)-N-ETHYLGLYCYL]ASPARTYL]-L-&bgr;-CYCLOHEXYL ALANINE AMIDE, INTERMEDIATES THEREOF, AND PREPARATION THEREOF AND OF ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES
    Patent number: 6753409
    Abstract: The invention is directed to a non-hygroscopic stable crystalline form of the antithrombotic compound N-[N-[N-(4-piperdin-4-yl)butanoyl)-N-ethylglycyl]-(L)-aspartyl]-(L)-&bgr;-cyclohexyl-alanine amide, to processes for preparing said stable crystalline form, to a pharmaceutical composition thereof, and intermediates thereof, and the invention is directed also to processes for preparing a compound of the formula wherein: A, B, Z, E1, E2, G, R, m, n, and p are as defined herein.
    Type: Grant
    Filed: August 15, 2000
    Date of Patent: June 22, 2004
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Zofia J. Chrzan, James J. Mencel, David Toledo-Velasquez, Vincent Windisch, Rick G. Woodward, Diane C. Salazar, Narasimha M. Vemuri, Anthony J. Gardetto, Matthew R. Powers, Gregory G. Kubiak, Robert C. Liu, Benoit J. Vanasse, James P. Sherbine, Walter Rodriguez, Adam W. Sledeski
  • Stable non-hygroscopic crystalline form of N-[N-[N-4-(piperidin-4-yl)butanoyl)-N-ethylglycyl] aspartyl]-L-.beta.-cyclohexyl alanine amide
    Patent number: 6153588
    Abstract: The invention is directed to a non-hygroscopic stable crystalline form of the antithrombotic compound N-[N-[N-(4-piperdin-4-yl)butanoyl)-N-ethylglycyl]-(L)-aspartyl]-(L)-.beta. -cyclohexyl-alanine amide, to processes for preparing said stable crystalline form, to a pharmaceutical composition thereof, and intermediates thereof, and the invention is directed also to processes for preparing a compound of the formula ##STR1## wherein: A, B, Z, E.sup.1, E.sup.2, G, R, m, n, and p are as defined herein.
    Type: Grant
    Filed: February 18, 1999
    Date of Patent: November 28, 2000
    Assignee: Aventis Pharmaceuticals Products Inc.
    Inventors: Zofia J. Chrzan, James J. Mencel, David Toledo-Velasquez, Vincent Windisch, Rick G. Woodward, Diane C. Salazar, deceased, Narasimha M. Vemuri, Anthony J. Gardetto, Matthew R. Powers, Gregory G. Kubiak, Robert C. Liu, Benoit J. Vanasse, James P. Sherbine, Walter Rodriguez, Adam W. Sledeski
  • Binding pharmaceuticals to ion exchange resins
    Patent number: 5413782
    Abstract: In a method in which an ionizable pharmaceutical material, such as theophylline, having a pharmaceutically-active anionic group is bonded to an anion exchange resin having cationic groups bonded to displacable anionic groups by bringing said material and said resin into contact with each other under conditions such that the pharmaceutically-active anionic group of said material is bonded to the cationic group of said resin and replaces the anionic group thereof, the improvement comprising effecting said contact in an environment which is substantially free of carbon dioxide and/or bicarbonate ion, a pharmacologically active composition comprising said pharmaceutically active anion and said resin, including a composition in which at least about 40% of the binding capacity of the resin comprises said pharmaceutically active anion, and a sustained release pharmaceutical composition, including enteric coated particles of the composition, and stabilizing said composition by maintaining it in an environment substan
    Type: Grant
    Filed: November 10, 1992
    Date of Patent: May 9, 1995
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Mark P. Warchol, Zofia J. Chrzan
  • Binding theophylline to ion exchange resins
    Patent number: 5162110
    Abstract: In a method in which an ionizable pharmaceutical material, such as theophylline, having a pharmaceutically-active anionic group is bonded to an anion exchange resin having cationic groups bonded to displacable anionic groups by bringing said material and said resin into contact with each other under conditions such that the pharmaceutically-active anionic group of said material is bonded to the cationic group of said resin and replaces the anionic group thereof, the improvement comprising effecting said contact in an environment which is substantially free of carbon dioxide and/or bicarbonate ion, a pharmacologically active composition comprising said pharmaceutically active anion and said resin, including a composition in which at least about 40% of the binding capacity of the resin comprises said pharmaceutically active anion, and a sustained release pharmaceutical composition, including enteric coated particles of the composition, and stabilizing said composition by maintaining it in an environment substan
    Type: Grant
    Filed: December 19, 1990
    Date of Patent: November 10, 1992
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Mark P. Warchol, Zofia J. Chrzan